YAVNE, Israel, May 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company
bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will
release financial results for the first quarter ended March 31, 2018 at 7:00 am Eastern time on Thursday, May 10, 2018.
Following the release, MediWound's management will host a conference call for the investment community beginning
at 8:30 a.m. Eastern time to discuss the financial results and to answer questions.
Shareholders and other interested parties may participate in the conference call by dialing 800-289-0438 (in the
U.S.) 1809 212 883 (Israel), or 323-794-2423 (outside the U.S. & Israel) and entering passcode 370010. The call also will be
broadcast live on the Internet on the Company’s website at http://ir.mediwound.com/events-and-presentations.
A replay of the call will be accessible two hours after its completion through May 24, 2018 by dialing
844-512-2921 (in the U.S.) or 412-317-6671 (outside the U.S.) and entering passcode 370010. The call will also be archived on the
Company website for 90 days at www.mediwound.com.
About MediWound Ltd.
MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel
therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and
other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®, received marketing authorization from
the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue,
known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel and Argentina.
NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissues.
MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of
chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a
clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits
from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and
efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more
information, please visit www.mediwound.com.
Contacts:
Sharon Malka
Chief Financial and Operations Officer
MediWound
ir@mediwound.co.il
Bob Yedid
Managing Director
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
